HomeCompareDNVVF vs EQR

DNVVF vs EQR: Dividend Comparison 2026

DNVVF yields 400.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DNVVF wins by $11437.78M in total portfolio value
10 years
DNVVF
DNVVF
● Live price
400.00%
Share price
$0.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11437.82M
Annual income
$7,667,192,697.76
Full DNVVF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — DNVVF vs EQR

📍 DNVVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDNVVFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DNVVF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DNVVF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DNVVF
Annual income on $10K today (after 15% tax)
$34,000.00/yr
After 10yr DRIP, annual income (after tax)
$6,517,113,793.10/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, DNVVF beats the other by $6,517,110,546.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DNVVF + EQR for your $10,000?

DNVVF: 50%EQR: 50%
100% EQR50/50100% DNVVF
Portfolio after 10yr
$5718.93M
Annual income
$3,833,598,258.68/yr
Blended yield
67.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

DNVVF
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DNVVF buys
0
EQR buys
0
No recent congressional trades found for DNVVF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDNVVFEQR
Forward yield400.00%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$11437.82M$40.5K
Annual income after 10y$7,667,192,697.76$3,819.61
Total dividends collected$11090.87M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: DNVVF vs EQR ($10,000, DRIP)

YearDNVVF PortfolioDNVVF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$50,700$40,000.00$11,248$547.57+$39.5KDNVVF
2$243,782$189,532.71$12,701$666.53+$231.1KDNVVF
3$1,112,560$851,713.55$14,405$814.59+$1.10MDNVVF
4$4,823,161$3,632,721.39$16,413$999.84+$4.81MDNVVF
5$19,879,046$14,718,264.42$18,795$1,232.92+$19.86MDNVVF
6$77,964,520$56,693,940.88$21,639$1,527.95+$77.94MDNVVF
7$291,226,244$207,804,207.46$25,057$1,903.80+$291.20MDNVVF
8$1,037,056,355$725,444,273.70$29,197$2,385.87+$1037.03MDNVVF
9$3,523,955,262$2,414,304,962.28$34,250$3,008.70+$3523.92MDNVVF
10$11,437,824,828$7,667,192,697.76$40,467$3,819.61+$11437.78MDNVVF

DNVVF vs EQR: Complete Analysis 2026

DNVVFStock

DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Oléoactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.

Full DNVVF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this DNVVF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DNVVF vs SCHDDNVVF vs JEPIDNVVF vs ODNVVF vs KODNVVF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.